Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is experiencing some short-term challenges, particularly with the discontinuation of the Resolve UTI test and a CMS matter, but the company's long-term prospects remain strong. Their flagship Exosome test has strong commercial traction and the company has recently announced positive coverage determinations for this test. The company is actively defending against the CMS matter and has taken steps to reposition its sales strategy for sustained growth. Despite a near-term decrease in revenue and updated guidance, MDxHealth's focus on personalized cancer diagnosis and treatment solidifies a positive outlook for the company's future performance.

Bears say

MDxHealth is facing some challenges with its recent acquisition of Exact Sciences' Oncotype DX GPS test, as the company is seeing slower-than-expected growth and potential recoupment of payments from Novitas. Additionally, the recent discontinuation of its Resolve UTI test and lower-than-expected test volumes in its recent quarter are cause for concern. However, the company's potential for growth with its ExoDx test and focus on strategic acquisitions could provide some upside in the future.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.